Shares of Portola Pharmaceuticals, Inc. (PTLA) are lower by 27.15% to $20.85 in active pre-market trading on Thursday after the company’s topline data from Phase 3 APEX study showed its oral anticoagulant was not superior to an injectable standard therapy in preventing blood clots in acutely ill patients. — Tesla Motors, Inc. (TSLA) shares are […]
View the full post at: Morning Buzz: Portola (PTLA), Tesla (TSLA), Apple (AAPL), KB Home (KBH)